Abstract
Objectives To investigate whether there is a causal effect of cardiometabolic traits on risk of sepsis and severe covid-19.
Design Mendelian randomisation analysis.
Setting UK Biobank and HUNT study population-based cohorts for risk of sepsis, and genome-wide association study summary data for risk of severe covid-19 with respiratory failure.
Participants 12,455 sepsis cases (519,885 controls) and 1,610 severe covid-19 with respiratory failure cases (2,205 controls).
Exposure Genetic variants that proxy body mass index (BMI), lipid traits, systolic blood pressure, lifetime smoking score, and type 2 diabetes liability - derived from studies considering between 188,577 to 898,130 participants.
Main outcome measures Risk of sepsis and severe covid-19 with respiratory failure.
Results Higher genetically proxied BMI and lifetime smoking score were associated with increased risk of sepsis in both UK Biobank (BMI: odds ratio 1.38 per standard deviation increase, 95% confidence interval [CI] 1.27 to 1.51; smoking: odds ratio 2.81 per standard deviation increase, 95% CI 2.09-3.79) and HUNT (BMI: 1.41, 95% CI 1.18 to 1.69; smoking: 1.93, 95% CI 1.02-3.64). Higher genetically proxied BMI and lifetime smoking score were also associated with increased risk of severe covid-19, although with wider confidence intervals (BMI: 1.75, 95% CI 1.20 to 2.57; smoking: 3.94, 95% CI 1.13 to 13.75). There was limited evidence to support associations of genetically proxied lipid traits, systolic blood pressure or type 2 diabetes liability with risk of sepsis or severe covid-19. Similar findings were generally obtained when using Mendelian randomization methods that are more robust to the inclusion of pleiotropic variants, although the precision of estimates was reduced.
Conclusions Our findings support a causal effect of elevated BMI and smoking on risk of sepsis and severe covid-19. Clinical and public health interventions targeting obesity and smoking are likely to reduce sepsis and covid-19 related morbidity, along with the plethora of other health-related outcomes that these traits adversely affect.
What is already known on this topic
Sepsis and severe covid-19 are major contributors to global morbidity and mortality.
Cardiometabolic risk factors have been associated with risk of sepsis and severe covid-19, but it is unclear if they are having causal effects.
What this study adds
Using Mendelian randomization analyses, this study provides evidence to support that higher body mass index and lifetime smoking score both increase risk of sepsis and severe covid-19 with respiratory failure.
Clinical and public health interventions targeting obesity and smoking are likely to reduce sepsis and covid-19 related morbidity, along with the plethora of other health-related outcomes that these traits adversely affect.
Competing Interest Statement
LSPM has consulted for DNAelectronics (2015-18), Dairy Crest (2017-2018), bioMerieux (2013-20), Pfizer (2018-2020), and Umovis Lab (2020), received speaker fees from Profile Pharma (2018), received research grants from the National Institute for Health Research (2013-2020), CW+ Charity (2018-2019), and Leo Pharma (2016), and received educational grants from Eumedica (2016-2018). DG is employed part-time by Novo Nordisk. All other authors have no conflicts of interest to declare.
Funding Statement
MJP is a funded by the Welsh Clinical Academic Training (WCAT) programme and is a participant in the NIH Graduate Partnership Program. AG1 is funded by a Medical Research Council Methodology Research Panel grant (RG88311). VW is supported by the Medical Research Council (MRC) Integrative Epidemiology Unit. The MRC and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_12013/1, MC_UU_12013/9, MC_UU_00011/1]. REW is supported by Wellcome Trust grant (204895/Z/16/Z). LSPM acknowledges the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre (BRC) and the NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London in partnership with Public Health England. NMD is supported by a Norwegian Research Council Grant number 295989. SB and AG2 are supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). DG is supported by the Wellcome 4i Program (203928/Z/16/Z) and British Heart Foundation Research Centre of Excellence (RE/18/4/34215) at Imperial College London. The funding sources did not have any role in designing the study, performing analysis or communicating findings.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in this work obtained relevant participant consent and ethical approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interest statement All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: LSPM has consulted for DNAelectronics (2015-18), Dairy Crest (2017–2018), bioMerieux (2013-20), Pfizer (2018-2020), and Umovis Lab (2020), received speaker fees from Profile Pharma (2018), received research grants from the National Institute for Health Research (2013-2020), CW+ Charity (2018-2019), and Leo Pharma (2016), and received educational grants from Eumedica (2016–2018). DG is employed part-time by Novo Nordisk. All other authors have no conflicts of interest to declare.
Transparency declaration The corresponding authors affirm that the manuscript is an honest, accurate, and transparent account of the research being reported, and that no important aspects of the study have been omitted.
Dissemination declaration This work uses genetic association summary data and dissemination to the participants that contributed these data is therefore not possible.
Copyright The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.
Funding MJP is a funded by the Welsh Clinical Academic Training (WCAT) programme and is a participant in the NIH Graduate Partnership Program. AG1 is funded by a Medical Research Council Methodology Research Panel grant (RG88311). VW is supported by the Medical Research Council (MRC) Integrative Epidemiology Unit. The MRC and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_12013/1, MC_UU_12013/9, MC_UU_00011/1]. REW is supported by Wellcome Trust grant (204895/Z/16/Z). LSPM acknowledges the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre (BRC) and the NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London in partnership with Public Health England. NMD is supported by a Norwegian Research Council Grant number 295989. SB and AG2 are supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). DG is supported by the Wellcome 4i Program (203928/Z/16/Z) and British Heart Foundation Research Centre of Excellence (RE/18/4/34215) at Imperial College London. The funding sources did not have any role in designing the study, performing analysis or communicating findings.
Data Availability
All variants used as instruments and their genetic association estimates were selected from publicly available data sources, and are provided in Supplementary Tables 2-6. The results from the analyses performed in this work are presented in the main manuscript or its supplementary files. This paper has been reported based on recommendations by the STROBE-MR Guidelines (Supplementary Research Checklist).41 The study protocol and details were not pre-registered. Code for analyses are available via the online Github repository (https://github.com/agkatzionis/Sepsis-MR).
